COVID-19 Therapeutic Alerts

Antivirals Or Neutralising Monoclonal Antibodies For Non-Hospitalised Patients With Covid-19

The published policy, providing access to monoclonal antibodies or antivirals as treatment options for non-hospitalised patients at highest risk from COVID-19 infection, has been updated.

These changes are for implementation from Thursday 10 February 2022.

Further information, the interim clinical commissioning policy and a clinical guide can be found on the CAS website.

Antivirals And Neutralising Monoclonal Antibodies In The Treatment Of Covid-19 In Hospitalised Patients

The published policy has been further updated (effective from 10 February 2022).

Further information, the interim clinical commissioning policy and a clinical guide can be found on the CAS website.